ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,021 to 3,040 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: serious adverse events37 of 1,209

37 of 1,212

0.0 points

-1.4 to 1.4

2,421NCT05505734

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: Incidence of All-cause Mortality61 of 1,212

72 of 1,207

-0.9 points

-2.8 to 0.9

2,419NCT02586155

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: deaths from any cause61 of 1,212

72 of 1,207

-0.9 points

-2.8 to 0.9

2,419NCT02586155

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: serious adverse events354 of 1,212

339 of 1,207

1.1 points

-2.5 to 4.7

2,419NCT02586155

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

Pimecrolimus vs Topical Corticosteroids: serious adverse events247 of 1,205

210 of 1,213

3.2 points

0.1 to 6.3

2,418NCT00120523

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Unexposed to Gastroenteritis vs Exposed to Gastroenteritis: Number of Participants With Post Infectious Irritable Bowel Syndrome23 of 829

114 of 1,586

-4.4 points

-6.1 to -2.6

2,415NCT00235326

Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario

Absorb BVS vs XIENCE: Number of Participants With Rehospitalization654 of 1,205

621 of 1,210

3.0 points

-1.0 to 6.9

2,415NCT02173379

Absorb IV Randomized Controlled Trial

Tenofovir Group vs Placebo Group: Number Participants Who Reported More Than One Sexual Partner at Baseline251 of 1,204

271 of 1,209

-1.6 points

-4.9 to 1.7

2,413NCT00119106

Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand

Tenofovir vs Placebo: Renal Toxicity3 of 1,204

3 of 1,209

0.0 points

-0.5 to 0.5

2,413NCT00119106

Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand

Tenofovir vs Placebo: Adverse Events1,098 of 1,204

1,083 of 1,209

1.6 points

-0.7 to 4.0

2,413NCT00119106

Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand

Tenofovir vs Placebo: deaths from any cause49 of 1,204

58 of 1,209

-0.7 points

-2.4 to 0.9

2,413NCT00119106

Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand

Tenofovir vs Placebo: serious adverse events227 of 1,204

246 of 1,209

-1.5 points

-4.7 to 1.7

2,413NCT00119106

Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand

Tenofovir vs Placebo: Number of Participants Reporting Injecting and Sharing Needles58 of 1,204

59 of 1,207

-0.1 points

-1.8 to 1.7

2,411NCT00119106

Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand

Palivizumab vs Motavizumab: The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups46 of 1,183

24 of 1,227

1.9 points

0.6 to 3.3

2,410NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Parenteral Nutrition vs Enteral Nutrition: Mortality422 of 1,208

443 of 1,202

-1.9 points

-5.7 to 1.9

2,410NCT01802099

Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines

V114 vs Prevnar 13™: deaths from any cause1 of 1,972

1 of 437

-0.2 points

-1.2 to 0.1

2,409NCT03692871

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Superimposed Preeclampsia295 of 1,208

373 of 1,200

-6.7 points

-10.2 to -3.1

2,408NCT02299414

Chronic Hypertension and Pregnancy (CHAP) Project

Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Neonatal Hospital Stay of 3 or More Days590 of 1,208

592 of 1,200

-0.5 points

-4.5 to 3.5

2,408NCT02299414

Chronic Hypertension and Pregnancy (CHAP) Project

Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Hypoglycemia191 of 1,208

195 of 1,200

-0.4 points

-3.4 to 2.5

2,408NCT02299414

Chronic Hypertension and Pregnancy (CHAP) Project

Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Low Birth Weight232 of 1,208

277 of 1,200

-3.9 points

-7.1 to -0.6

2,408NCT02299414

Chronic Hypertension and Pregnancy (CHAP) Project

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=152"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=152

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT05505734-sae",
        "title": "BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: serious adverse events",
        "summary": "37 of 1209 against 37 of 1212; risk difference 0.0 points, 95% interval -1.4 to 1.4; NCT05505734, A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma",
        "record": "/library/comparisons/NCT05505734-sae",
        "nct_id": "NCT05505734",
        "kind": "serious-adverse-events",
        "participants": 2421,
        "risk_difference": {
          "value": 0.00007575199207265557,
          "lower": -0.013929881750434388,
          "upper": 0.01409123103724802
        },
        "group_1": "37 of 1,209",
        "group_2": "37 of 1,212",
        "difference": "0.0 points",
        "interval": "-1.4 to 1.4",
        "trial_title": "A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma"
      },
      {
        "id": "NCT02586155-59a8daa2",
        "title": "High-Intensity Statin Therapy+RVX000222 vs High-Intensity Statin Therapy+Placebo: Incidence of All-cause Mortality",
        "summary": "61 of 1212 against 72 of 1207; risk difference -0.9 points, 95% interval -2.8 to 0.9; NCT02586155, Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD",
        "record": "/library/comparisons/NCT02586155-59a8daa2",
        "nct_id": "NCT02586155",
        "kind": "outcome",
        "participants": 2419,
        "risk_difference": {
          "value": -0.009321996822714583,
          "lower": -0.027740500883247515,
          "upper": 0.008969777700720643
        },
        "group_1": "61 of 1,212",
        "group_2": "72 of 1,207",
        "difference": "-0.9 points",
        "interval": "-2.8 to 0.9",
        "trial_title": "Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=153",
  "request_id": "pAfkOc8K1aK-8n0k"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?